Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis

类风湿性关节炎的脂质、炎症和心血管风险

• 批准号: 9028324
• 负责人: Katherine Phoenix Liao
• 金额: $ 89.37万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2021-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9028324
• 关键词: Anatomy; Anti-Inflammatory Agents; Anti-Tumor Necrosis Factor Therapy; Anti-inflammatory; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Blood; Blood Vessels; Blood specimen; C-reactive protein; Cardiac; Cardiovascular system; Categories; Cholesterol; Clinical; Coronary; Data; Development; Disease; Disease remission; Event; General Population; Heart; Heart Diseases; High Density Lipoprotein Cholesterol; High Density Lipoproteins; Human; Image; Imaging Techniques; Inflammation; Injury; Intervention; Knowledge; LDL Cholesterol Lipoproteins; Lead; Link; Lipids; Lipoprotein (a); Lipoproteins; Longitudinal Studies; Low-Density Lipoproteins; Measurement; Measures; Methods; Mission; Modeling; Myocardial; Myocardial perfusion; National Heart, Lung, and Blood Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Observational Study; Outcome; Particle Size; Patients; Physiological; Positron-Emission Tomography; Public Health; Recruitment Activity; Research; Rheumatism; Rheumatoid Arthritis; Risk; Risk Estimate; Risk Factors; Role; Stress; Surrogate Markers; TNF gene; Testing; Time; Troponin T; Vasomotor; arthritis therapy; cardiovascular risk factor; clinically significant; cohort; follow-up; heart disease risk; improved; inclusion criteria; inflammatory marker; innovation; insight; mortality; prevent; prospective; public health relevance; research study; rheumatologist

 DESCRIPTION (provided by applicant): Patients with rheumatoid arthritis (RA) are at 1.5x risk for heart disease risk compared to the general population. Effective RA therapies which reduce inflammation such as tumor necrosis factor antagonists (anti- TNF), increase levels of low density lipoprotein cholesterol (LDL-C) suggesting that treatment may increase the burden of heart disease. However, large observational studies suggest the opposite: anti-TNF therapies are independently associated with reduced heart disease risk. While inflammation may explain these seemingly paradoxical findings, the exact mechanisms are poorly understood. A gap in knowledge exists regarding how rheumatologists should weigh changes in lipid levels with treatment and level of inflammation when assessing for risk of heart disease in RA. The objective of this proposal is to determine the clinical significance of increased LDL-C levels in associated with reduction in inflammation by anti-TNF therapy, and directly test the association of changes in inflammation with changes in lipid levels and risk of heart disease. The central hypothesis of this study is that reducing inflammation will be associated with reduced heart disease risk in RA. We will further determine whether advanced lipoprotein measures, including apolipoprotein B and A1 levels, LDL particle size and HDL function may be better markers of heart disease risk in RA patients. The Aims of this project are to: (1) study the longitudinal association between changes in inflammation with changes in advanced lipoprotein measures, (2) determine the effect of reducing inflammation with anti-TNF therapy on markers of injury and vascular function in the heart, (3) examine the effect of reducing inflammation on changes in advanced lipoprotein measures, and association with heart disease risk in RA. Aim 1 will be conducted using data and blood samples collected annually from a prospective longitudinal RA cohort. Subjects (N=200) with significant changes in inflammation between two consecutive years will be identified and their blood samples measured for inflammatory markers, lipids and advanced lipoprotein tests. In Aims 2 and 3, RA patients (N=75) about to initiate anti-TNF therapy will be recruited, and prospectively studied for changes in inflammatory markers, routine lipids and advanced lipoprotein measures before and at 6, 12, and 24 weeks after starting anti-TNF. Subjects will undergo cardiac PET imaging to calculate coronary flow reserve (CFR) at baseline and 24 weeks. CFR measures coronary vascular function and is a validated surrogate marker for heart disease risk. This approach is innovative because it leverages RA as a human model of inflammation. In this experiment anti-TNF is repurposed as an intervention to reduce inflammation in order to study associated changes in lipids and risk for heart disease. The study is significant because it may transform the way heart disease risk is assessed in RA, by informing development of an integrated approach using comprehensive lipid measurements and level of inflammation. Results from this study may also have implications for the general population where inflammation has a smaller but significant role in the risk of heart disease.

 描述（由申请人提供）：与普通人群相比，类风湿性关节炎（RA）患者患心脏病的风险为1.5倍。有效的RA疗法可减少炎症，例如肿瘤坏死因子拮抗剂（抗TNF），增加低密度脂蛋白胆固醇（LDL-C）水平，这表明治疗可能会增加心脏病的负担。然而，大型观察性研究表明相反：抗TNF治疗与降低心脏病风险独立相关。虽然炎症可以解释这些看似矛盾的发现，但确切的机制知之甚少。在评估RA心脏病风险时，关于风湿病学家应如何权衡治疗和炎症水平的脂质水平变化，存在知识差距。本提案的目的是确定LDL-C水平升高与抗TNF治疗减轻炎症相关的临床意义，并直接测试炎症变化与脂质水平变化和心脏病风险的相关性。这项研究的中心假设是，减少炎症将与降低RA的心脏病风险有关。我们将进一步确定是否先进的脂蛋白措施，包括载脂蛋白B和A1水平，LDL颗粒大小和HDL功能可能是更好的标记物的心脏病风险的RA患者。本项目的目的是：（1）研究炎症变化与晚期脂蛋白指标变化之间的纵向关联，（2）确定抗TNF治疗减轻炎症对心脏损伤和血管功能标志物的影响，（3）检查减轻炎症对晚期脂蛋白指标变化的影响，以及与RA心脏病风险的关联。目标1将使用每年从前瞻性纵向RA队列中收集的数据和血液样本进行。将确定连续两年之间炎症显著变化的受试者（N=200），并测量其血液样本的炎症标志物、脂质和高级脂蛋白试验。在目的2和3中，将招募即将开始抗TNF治疗的RA患者（N=75），并前瞻性研究开始抗TNF治疗前和治疗后6、12和24周时炎性标志物、常规脂质和晚期脂蛋白指标的变化。受试者将接受心脏PET成像，以计算基线和24周时的冠状动脉血流储备（CFR）。CFR测量冠状动脉血管功能，是心脏病风险的有效替代标志物。这种方法是创新的，因为它利用RA作为人类炎症模型。在这项实验中，抗TNF被重新用作减少炎症的干预措施，以研究脂质和心脏病风险的相关变化。这项研究具有重要意义，因为它可能会改变评估RA心脏病风险的方式，通过使用全面的脂质测量和炎症水平来开发综合方法。这项研究的结果也可能对普通人群产生影响，因为炎症在心脏病风险中的作用较小但很重要。